Another humanized anti-CD33 monoclonal antibody, Gemtuzumab Ozogamicin, is an antibody drug-conjugate linked to calicheamicin that was validated as an AML treatment by increased clinical efficacy in a Phase II clinical trial. Here, CD33 is linked to acute myeloid leukemia.